272 related articles for article (PubMed ID: 18286565)
1. Intradermal NKT cell activation during DNA priming in heterologous prime-boost vaccination enhances T cell responses and protection against Leishmania.
Dondji B; Deak E; Goldsmith-Pestana K; Perez-Jimenez E; Esteban M; Miyake S; Yamamura T; McMahon-Pratt D
Eur J Immunol; 2008 Mar; 38(3):706-19. PubMed ID: 18286565
[TBL] [Abstract][Full Text] [Related]
2. TLR1/2 activation during heterologous prime-boost vaccination (DNA-MVA) enhances CD8+ T Cell responses providing protection against Leishmania (Viannia).
Jayakumar A; Castilho TM; Park E; Goldsmith-Pestana K; Blackwell JM; McMahon-Pratt D
PLoS Negl Trop Dis; 2011 Jun; 5(6):e1204. PubMed ID: 21695103
[TBL] [Abstract][Full Text] [Related]
3. Heterologous priming-boosting with DNA and vaccinia virus expressing kinetoplastid membrane protein-11 induces potent cellular immune response and confers protection against infection with antimony resistant and sensitive strains of Leishmania (Leishmania) donovani.
Guha R; Das S; Ghosh J; Naskar K; Mandala A; Sundar S; Dujardin JC; Roy S
Vaccine; 2013 Apr; 31(15):1905-15. PubMed ID: 23499564
[TBL] [Abstract][Full Text] [Related]
4. Induction of protective CD4+ T cell-mediated immunity by a Leishmania peptide delivered in recombinant influenza viruses.
Kedzierska K; Curtis JM; Valkenburg SA; Hatton LA; Kiu H; Doherty PC; Kedzierski L
PLoS One; 2012; 7(3):e33161. PubMed ID: 22470440
[TBL] [Abstract][Full Text] [Related]
5. The combination of DNA vectors expressing IL-12 + IL-18 elicits high protective immune response against cutaneous leishmaniasis after priming with DNA-p36/LACK and the cytokines, followed by a booster with a vaccinia virus recombinant expressing p36/LACK.
Tapia E; Pérez-Jiménez E; López-Fuertes L; Gonzalo R; Gherardi MM; Esteban M
Microbes Infect; 2003 Feb; 5(2):73-84. PubMed ID: 12650765
[TBL] [Abstract][Full Text] [Related]
6. Requirements for the maintenance of Th1 immunity in vivo following DNA vaccination: a potential immunoregulatory role for CD8+ T cells.
Gurunathan S; Stobie L; Prussin C; Sacks DL; Glaichenhaus N; Iwasaki A; Fowell DJ; Locksley RM; Chang JT; Wu CY; Seder RA
J Immunol; 2000 Jul; 165(2):915-24. PubMed ID: 10878366
[TBL] [Abstract][Full Text] [Related]
7. High quality long-term CD4+ and CD8+ effector memory populations stimulated by DNA-LACK/MVA-LACK regimen in Leishmania major BALB/c model of infection.
Sánchez-Sampedro L; Gómez CE; Mejías-Pérez E; Sorzano CO; Esteban M
PLoS One; 2012; 7(6):e38859. PubMed ID: 22715418
[TBL] [Abstract][Full Text] [Related]
8. MVA-LACK as a safe and efficient vector for vaccination against leishmaniasis.
Pérez-Jiménez E; Kochan G; Gherardi MM; Esteban M
Microbes Infect; 2006 Mar; 8(3):810-22. PubMed ID: 16504562
[TBL] [Abstract][Full Text] [Related]
9. Antigenicity of
Fernández L; Carrillo E; Sánchez-Sampedro L; Sánchez C; Ibarra-Meneses AV; Jimenez MA; Almeida VDA; Esteban M; Moreno J
Front Immunol; 2018; 9():843. PubMed ID: 29740446
[No Abstract] [Full Text] [Related]
10. Persistence of protective immunity to malaria induced by DNA priming and poxvirus boosting: characterization of effector and memory CD8(+)-T-cell populations.
Sedegah M; Brice GT; Rogers WO; Doolan DL; Charoenvit Y; Jones TR; Majam VF; Belmonte A; Lu M; Belmonte M; Carucci DJ; Hoffman SL
Infect Immun; 2002 Jul; 70(7):3493-9. PubMed ID: 12065488
[TBL] [Abstract][Full Text] [Related]
11. Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response.
Ramos I; Alonso A; Marcen JM; Peris A; Castillo JA; Colmenares M; Larraga V
Vaccine; 2008 Jan; 26(3):333-44. PubMed ID: 18093705
[TBL] [Abstract][Full Text] [Related]
12. A prime/boost DNA/Modified vaccinia virus Ankara vaccine expressing recombinant Leishmania DNA encoding TRYP is safe and immunogenic in outbred dogs, the reservoir of zoonotic visceral leishmaniasis.
Carson C; Antoniou M; Ruiz-Argüello MB; Alcami A; Christodoulou V; Messaritakis I; Blackwell JM; Courtenay O
Vaccine; 2009 Feb; 27(7):1080-6. PubMed ID: 19095029
[TBL] [Abstract][Full Text] [Related]
13. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis.
Iborra S; Soto M; Carrión J; Alonso C; Requena JM
Vaccine; 2004 Sep; 22(29-30):3865-76. PubMed ID: 15364433
[TBL] [Abstract][Full Text] [Related]
14. Perforin and gamma interferon expression are required for CD4+ and CD8+ T-cell-dependent protective immunity against a human parasite, Trypanosoma cruzi, elicited by heterologous plasmid DNA prime-recombinant adenovirus 5 boost vaccination.
de Alencar BC; Persechini PM; Haolla FA; de Oliveira G; Silverio JC; Lannes-Vieira J; Machado AV; Gazzinelli RT; Bruna-Romero O; Rodrigues MM
Infect Immun; 2009 Oct; 77(10):4383-95. PubMed ID: 19651871
[TBL] [Abstract][Full Text] [Related]
15. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major.
Gurunathan S; Sacks DL; Brown DR; Reiner SL; Charest H; Glaichenhaus N; Seder RA
J Exp Med; 1997 Oct; 186(7):1137-47. PubMed ID: 9314562
[TBL] [Abstract][Full Text] [Related]
16. Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein.
Fujii S; Shimizu K; Smith C; Bonifaz L; Steinman RM
J Exp Med; 2003 Jul; 198(2):267-79. PubMed ID: 12874260
[TBL] [Abstract][Full Text] [Related]
17. IL-10 from regulatory T cells determines vaccine efficacy in murine Leishmania major infection.
Stober CB; Lange UG; Roberts MT; Alcami A; Blackwell JM
J Immunol; 2005 Aug; 175(4):2517-24. PubMed ID: 16081824
[TBL] [Abstract][Full Text] [Related]
18. Optimization of DNA vaccination against cutaneous leishmaniasis.
Méndez S; Belkaid Y; Seder RA; Sacks D
Vaccine; 2002 Nov; 20(31-32):3702-8. PubMed ID: 12399198
[TBL] [Abstract][Full Text] [Related]
19. Heterologous prime-boost vaccination with the LACK antigen protects against murine visceral leishmaniasis.
Dondji B; Pérez-Jimenez E; Goldsmith-Pestana K; Esteban M; McMahon-Pratt D
Infect Immun; 2005 Aug; 73(8):5286-9. PubMed ID: 16041057
[TBL] [Abstract][Full Text] [Related]
20. CD4+ TH1 cells generated by Ii-PADRE DNA at prime phase are important to induce effectors and memory CD8+ T cells.
Park JY; Jin DH; Lee CM; Jang MJ; Lee SY; Shin HS; Chung YH; Kim KY; Kim SS; Lee WB; Shin YK; Lee WJ; Park YM; Kim D
J Immunother; 2010 Jun; 33(5):510-22. PubMed ID: 20463596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
